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HODGES Et al. non-seasonal influenza virus susceptibility to NAIs because of difficulty of acquiring and testing large numbers of each distinct subtype and wide range of genetic lineages within each subtype. Moreover, NAI results require careful interpretation, as laboratory correlates of clinically relevant resistance have not been established, except for viruses carrying an N1 NA with the H275Y substitution. 5 Infections caused by viruses displaying reduced inhibition (RI) or highly reduced inhibition (HRI) phenotypes may be more difficult to control by therapeutic intervention, which can lead to prolonged illness and virus shedding. 6 Simple and rapid assays that can be used by surveillance laboratories and in clinical settings are needed to detect viruses with reduced susceptibility to NAIs. As previously reported, the prototype influenza antiviral resistance test (iART), developed by BD Technologies (BARDA Contract HHSO100201300008C), is able to phenotypically detect seasonal influenza viruses that display RI/HRI by oseltamivir. 7 This assay compares influenza-specific sialidase (NA) activity with and without a single drug concentration, requires only 1 hour, and does not need extensive training to carry out. Here, we present similar findings for zoonotic and animal influenza viruses.
| COMPARISON OF IART TO NAI A SSAY
To verify the ability of iART to efficiently detect NA enzymatic activity and inhibition by oseltamivir of various subtypes (N1 through N9), a variety of zoonotic and animal influenza viruses were tested. This included viruses (n = 45) isolated from wild birds, poultry, a domestic cat, and zoonotic human infections propagated in MDCK cells or fertilized chicken eggs (Table 1) . NA sequence analysis did not identify known or suspected markers of resistance to oseltamivir (Table S1 ). Viruses were tested using both the fluorescence-based NAI and iART assays, as previously described. 4 All virus isolates were found to be susceptible to inhibition by oseltamivir in the iART assay (R-factor ≤0.70). In the NAI assay, all calculated IC 50 values were in the nanomolar/subnanomolar range; some differences among subtypes were observed, as expected, with the greatest IC 50 value observed for N8 viruses and the lowest for N2 viruses ( A wide range of R-factors were observed, which correlated with the range of fold differences determined by NAI assay ( Figure S1 ). Table 1 or seasonal viruses reported previously would be flagged as having potentially reduced susceptibility using a lower threshold for type A viruses. 
| RECOMB INANT N9 PROTEIN S WITH K NOWN MARK ER S OF RI/HRI BY OS ELTAMIVIR
Amino acid substitutions known to reduce susceptibility to oseltamivir E119V, I222K/R, H274Y, R292K, and R371K (N2 numbering) have been detected in the NA of A(H7N9) viruses isolated from humans. 8 In addition, I222T was detected in an A(H7N9) virus isolated from a non-human primate after oseltamivir treatment. 9 To determine whether iART is able to identify NA with these changes as resistant to oseltamivir, the respective recombinant N9 (rN9) proteins were generated using the A/Shanghai/2/2013 NA as a backbone, as previously described. 10 The use of recombinant protein allows testing of amino acid changes that reduce enzymatic activity in addition to reducing susceptibility to NAIs, including R292K (R289K in N9 straight numbering), the most commonly identified NA change detected in H7N9 human cases. The R-factors of rN9 proteins carrying substitutions E119V, I222K/R, H274Y, R292K, or R371K categorized them as resistant to oseltamivir and correlated with NAI assay outcomes ( Table 3 ). The range of R-factors also correlated with the range of TA B L E 1 Zoonotic and avian influenza A viruses of the N1-N9 neuraminidase (NA) subtypes and NA inhibitor (NAI) activity Criteria for interpreting NAI assay results based on IC 50 fold increase compared with the control virus/median IC 50 value: normal inhibition (NI) <10-fold, reduced inhibition (RI) 10-to 100-fold, and highly reduced inhibition (HRI) >100-fold.
TA B L E 2 Zoonotic and avian influenza A viruses with neuraminidase (NA) substitutions conferring (highly) reduced inhibition by oseltamivir
d R-factor: ratio of chemiluminescent signal intensity generated by viral NA activity with and without inhibitor (ie, oseltamivir carboxylate). R-factor interpretation based on pre-set cutoff for influenza A (resistance is ≥0.70).
IC 50 values ( Figure S1 ); all rN9 with R-factors above 2.0 were identified as having HRI by the NAI assay. The rN9 protein with I222T was identified as non-resistant by iART. In the NAI assay, the fold change conferred by this substitution was below the threshold of 10, further confirming the correlation between the two assays.
| IART VS NAI A SSAY UNDER LOW PH COND ITI ON S (PH 5. 3 VS 6 . 8)
As mentioned above, R292K is the most commonly reported NA marker in oseltamivir-treated patients infected with A(H7N9) viruses.
In addition, this change is also known to reduce enzymatic activity, making detection of drug resistance difficult using the standard NAI assay due to insufficient activity for testing or wild-type activity masking resistance. 11 It was previously reported that detection of R292K viruses could be improved by NAI testing at an acidic pH.
12
To confirm this finding, testing was performed on a highly pathogenic avian influenza A(H7N9) isolate, A/Taiwan/1/2017, containing the R292K substitution. At a standard pH of 6.8, the NAI assay was unable to test this virus isolate as NA activity was below the threshold needed for testing (Table 4) . At a pH of 5.3, however, this virus had sufficient NA activity and displayed an HRI phenotype. Notably, iART was able to detect resistance caused by R292K, without modifying the pH conditions of the assay. We previously showed that clinical specimens can be tested directly by iART, even when NA activity is insufficient for testing by NAI. 7 These results confirm and extend those findings and suggest the greater sensitivity of iART to detect resistance in low-activity NA viruses.
Influenza antiviral resistance test is a rapid and sensitive phenotypic assay for the detection of influenza viruses with reduced inhibition by oseltamivir. Unlike sequence-based methods, iART provides phenotypic data that are valuable for the identification of viruses carrying both known and unknown molecular markers TA B L E 3 Recombinant neuraminidase (NA) proteins of A/Shanghai/2/2013 (H7N9) with substitutions conferring (highly) reduced inhibition by oseltamivir associated with reduced susceptibility. As new animal and zoonotic subtype viruses emerge, it is critical to determine their drug phenotype rapidly so that public health authorities and clinicians can better assess treatment options. iART is currently not commercially available, though another influenza-specific assay (QFlu Combo Test by Cellex) uses a similar principal of oseltamivir resistance detection.
The future availability of iART depends on demand for point of care assays to detect antiviral resistance.
While the gold standard NAI assay continues to be the assay of choice for surveillance laboratories, it is cumbersome and requires highly trained personnel. iART provides an alternative, simple method for detecting oseltamivir-resistant viruses using a small and portable device with built-in software for data interpretation.
Viruses detected by iART with elevated R-factors can be flagged for genetic analysis and comprehensive phenotypic evaluation. This design and ease of use may allow oseltamivir susceptibility testing in locations currently unable to carry out the NAI assay.
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